Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
153 hedge funds and large institutions have $198M invested in Clovis Oncology, Inc. in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 39 reducing their positions, and 27 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 27
3% less funds holding
Funds holding: 157 → 153 (-4)
28% less call options, than puts
Call options by funds: $4.29M | Put options by funds: $5.93M
32% less capital invested
Capital invested by funds: $292M → $198M (-$94.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$5.35M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.32M |
| 3 |
Rafferty Asset Management
New York
|
+$2.29M |
| 4 |
Citigroup
New York
|
+$2.06M |
| 5 |
QF
QVT Financial
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.06M |
| 2 |
Morgan Stanley
New York
|
-$2.48M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$1.8M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$914K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$739K |
CLVS Hedge Fund Activity: Q4 2021 in Review
153 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2021, worth a combined $198M — down 32% from $292M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CLVS and 26 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 54 added.
The largest buyer was Bank of America, adding an estimated $5.35M. The largest seller was Vanguard Group, cutting an estimated $8.06M.
- 153 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2021, down from 157 in Q3 2021.
- Funds reported $198M of Clovis Oncology, Inc. stock for Q4 2021, down 32% quarter-over-quarter.
- 26 funds opened new Clovis Oncology, Inc. positions in Q4 2021 and 27 closed out, a net change of -1 holder.
- The largest Clovis Oncology, Inc. buyer in Q4 2021 was Bank of America, an estimated $5.35M added.
- The largest Clovis Oncology, Inc. seller in Q4 2021 was Vanguard Group, an estimated $8.06M sold.
Based on aggregated 13F filings for Q4 2021.